Viewing Study NCT04042402

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:02 AM
Ignite Modification Date: 2026-01-25 @ 12:02 AM
Study NCT ID: NCT04042402
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-30
First Post: 2019-07-10
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Long Term Extension Study in Patients With Primary Hyperoxaluria
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Hyperoxaluria Type 1 (PH1) View
None Primary Hyperoxaluria Type 2 (PH2) View
None Kidney Diseases View
None Urologic Diseases View
None Genetic Disease View
None Primary Hyperoxaluria Type 3 (PH3) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Primary Hyperoxaluria View
None PH1 View
None PH2 View
None RNAi View
None GalNAc View
None LDHA View
None LDH View
None siRNA View
None PH3 View